This is an important study that identifies the developmental time window during which re-expression of TCF4 mutated in Pitt-Hopkins syndrome, can rescue phenotypic features of brain function in a TCF4 ...

A research team at the IPK Leibniz Institute has developed a method that enables the detailed observation of female ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

Researchers from New England Biolabs and Yale University have created a system for engineering the first fully synthetic ...

Retrotransposons are pivotal in human genome evolution, driving structural variation and regulatory innovation while influencing health and disease.

Tempus AI launched its HRD-RNA algorithm, an AI-driven model for identifying Homologous Recombination Deficiency in cancer patients. The company also partnered with Median Technologies to integrate ...

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 3.5% Wednesday after the precision medicine technology company announced the launch of its new HRD-RNA algorithm for cancer detection.

Accent Therapeutics launched a Phase I/II clinical trial last year to begin testing a small molecule inhibitor of KIF18A in ovarian cancers.

A study published in Nature has established the first direct link between common genetic variants in mothers and the risk of ...

Antimicrobial resistance (AMR) represents a growing global health crisis, progressively undermining the efficacy of traditional antimicrobial therapies. The ...

UNSW researchers have developed an intrinsic-adjusted single-diode model that explicitly accounts for radiative and Auger recombination, improving I–V curve accuracy and reducing root mean square ...